Literature DB >> 16911479

Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.

Udo Rüb1, Rob A I de Vos, Ewout R Brunt, Tamás Sebestény, Ludger Schöls, Georg Auburger, Jürgen Bohl, Estifanos Ghebremedhin, Kristin Gierga, Kay Seidel, Wilfred den Dunnen, Helmut Heinsen, Henry Paulson, Thomas Deller.   

Abstract

In the last years progress has been made regarding the involvement of the thalamus during the course of the currently known polyglutamine diseases. Although recent studies have shown that the thalamus consistently undergoes neurodegeneration in Huntington's disease (HD) and spinocerebellar ataxia type 2 (SCA2) it is still unclear whether it is also a consistent target of the pathological process of spinocerebellar ataxia type 3 (SCA3). Accordingly we studied the thalamic pathoanatomy and distribution pattern of ataxin-3 immunopositive neuronal intranuclear inclusions (NI) in nine clinically diagnosed and genetically confirmed SCA3 patients and carried out a detailed statistical analysis of our findings. During our pathoanatomical study we disclosed (i) a consistent degeneration of the ventral anterior, ventral lateral and reticular thalamic nuclei; (ii) a degeneration of the ventral posterior lateral nucleus and inferior and lateral subnuclei of the pulvinar in the majority of these SCA3 patients; and (iii) a degeneration of the ventral posterior medial and lateral posterior thalamic nuclei, the lateral geniculate body and some of the limbic thalamic nuclei in some of them. Upon immunocytochemical analysis we detected NI in all of the thalamic nuclei of all of our SCA3 patients. According to our statistical analysis (i) thalamic neurodegeneration and the occurrence of ataxin-3 immunopositive thalamic NI was not associated with the individual length of the CAG-repeats in the mutated SCA3 allele, the patients age at disease onset and the duration of SCA3 and (ii) thalamic neurodegeneration was not correlated with the occurrence of ataxin-3 immunopositive thalamic NI. This lack of correlation may suggest that ataxin-3 immunopositive NI are not immediately decisive for the fate of affected nerve cells but rather represent unspecific and pathognomonic morphological markers of SCA3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911479     DOI: 10.1111/j.1750-3639.2006.00022.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  23 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas.

Authors:  Pedro Braga-Neto; Lívia Almeida Dutra; José Luiz Pedroso; André C Felício; Helena Alessi; Ruth F Santos-Galduroz; Paulo Henrique F Bertolucci; Mário Luiz V Castiglioni; Rodrigo Affonseca Bressan; Griselda Esther Jara de Garrido; Orlando Graziani Povoas Barsottini; Andrea Jackowski
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

Review 3.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

Review 4.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Stable polyglutamine dimers can contain β-hairpins with interdigitated side chains-but not α-helices, β-nanotubes, β-pseudohelices, or steric zippers.

Authors:  Markus S Miettinen; Luca Monticelli; Praveen Nedumpully-Govindan; Volker Knecht; Zoya Ignatova
Journal:  Biophys J       Date:  2014-04-15       Impact factor: 4.033

6.  Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3).

Authors:  W Scherzed; E R Brunt; H Heinsen; R A de Vos; K Seidel; K Bürk; L Schöls; G Auburger; D Del Turco; T Deller; H W Korf; W F den Dunnen; U Rüb
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

7.  B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy.

Authors:  Isabella Palazzolo; Natalia B Nedelsky; Caitlin E Askew; George G Harmison; Aleksey G Kasantsev; J Paul Taylor; Kenneth H Fischbeck; Maria Pennuto
Journal:  J Neurosci Res       Date:  2010-08-01       Impact factor: 4.164

8.  Axonal inclusions in spinocerebellar ataxia type 3.

Authors:  Kay Seidel; Wilfred F A den Dunnen; Christian Schultz; Henry Paulson; Stefanie Frank; Rob A de Vos; Ewout R Brunt; Thomas Deller; Harm H Kampinga; Udo Rüb
Journal:  Acta Neuropathol       Date:  2010-07-16       Impact factor: 17.088

Review 9.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

10.  Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.

Authors:  Anabela Silva-Fernandes; Sara Duarte-Silva; Andreia Neves-Carvalho; Marina Amorim; Carina Soares-Cunha; Pedro Oliveira; Kenneth Thirstrup; Andreia Teixeira-Castro; Patrícia Maciel
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.